MRNA monthly performance report
Explore MRNA's monthly returns, drawdown, and seasonality trends — updated every month.
MRNA monthly report
—
Key takeaways
- Moderna (MRNA) closed September 2026 at $158.07, up 12.63% for the month and +532.28% over the trailing 12 months.
- Year-to-date, MRNA is +436.01%, outperforming the S&P 500 which has returned +11.83% YTD.
- The stock is trading +168.99% versus its 200-day moving average ($58.76), a bullish technical signal.
- Over the past three years, MRNA has underperformed the S&P 500 by −34.06%, with a relative strength index reading of 88.3.
- Win rate over the trailing 39 months stands at 48.7% — 19 positive months versus 20 negative months.
Moderna ended September 2026 at $158.07, posting a monthly return of +12.63%. The S&P 500 returned −0.58% over the same window, leaving relative performance at +13.21%.
The current quarter stands at +125.72% (Q3 2026 (QTD)), while medium-term trend remains constructive: price is +168.99% versus the 200-day moving average ($58.76).
Year-to-date, MRNA is +436.01% against SPY +11.83%, a gap of +424.18%. The stock is currently −10.52% below its 52-week high, with maximum 3-year drawdown at −86.58%.
| Period | MRNA | S&P 500 (SPY) | Excess return |
|---|---|---|---|
| 1 Day | +8.55% | +1.13% | +7.42% |
| 1 Week | +15.70% | +0.63% | +15.07% |
| 1 Month | +12.63% | −0.58% | +13.21% |
| 3 Months | +185.32% | +1.64% | +183.69% |
| 6 Months | +200.74% | +15.15% | +185.60% |
| YTD | +436.01% | +11.83% | +424.18% |
| 12 Months | +532.28% | +15.69% | +516.59% |
| 3 Years | +37.94% | +72.00% | −34.06% |
| Rank | Month | Return |
|---|---|---|
| #1 | Aug 2026 | +156.00% |
| #2 | Jan 2026 | +49.44% |
| #3 | Jun 2026 | +48.40% |
| #4 | May 2024 | +29.23% |
| #5 | Dec 2023 | +27.99% |
| Rank | Month | Return |
|---|---|---|
| #1 | Aug 2024 | −35.08% |
| #2 | Oct 2023 | −26.46% |
| #3 | Jul 2026 | −21.72% |
| #4 | Feb 2025 | −21.46% |
| #5 | Nov 2024 | −20.79% |
| Quarter | Return |
|---|---|
| Q2 2025 | −2.68% |
| Q3 2025 | −6.38% |
| Q4 2025 | +14.17% |
| Q1 2026 | +72.26% |
| Q2 2026 | +37.85% |
| Q3 2026 (QTD) | +125.72% |
| Year | Return |
|---|---|
| 2023 | −44.63% |
| 2024 | −58.19% |
| 2025 | −29.08% |
| 2026 | +436.01% |
| Metric | Value |
|---|---|
| 52-Week High | $176.66 (2026-08-19) |
| 52-Week Low | $22.28 (2025-11-21) |
| Current Price | $158.07 |
| 200-Day Moving Average | $58.76 |
| Price vs 200DMA | +168.99% |
| 3-Year Maximum Drawdown | −86.58% (2025-11-20) |
| Current Drawdown from 52W High | −10.52% |
| RS metric | Value |
|---|---|
| RS Index (3-year, rebased to 100) | 88.3 |
| 3-Year Excess Return vs S&P 500 | −34.06% |
| RS Peak | 134.1 (May 2024) |
| RS Trough | 14.6 (Nov 2025) |
| Status | Underperforming Benchmark |
Frequently asked questions
What was MRNA's return for this report period?
MRNA returned +12.63% in the latest monthly window ending 2026-09-17.
Has MRNA outperformed SPY year to date?
YTD MRNA: +436.01% vs SPY: +11.83%.
What is MRNA's 12-month return?
+532.28% over the trailing 12 months.
Is MRNA above or below its 200-day moving average?
Price is +168.99% versus 200DMA ($58.76).
What is the maximum drawdown in the 3-year window?
−86.58% on 2025-11-20.